All News

hospital-834152_640.jpg

Steroid-Sparing Rituximab in Polymyalgia Rheumatica

Jack Cush, MD

BRIDGE-PMR proof-of-concept trial assessed the efficacy of rituximab (RTX) in patients with polymyalgia rheumatica (PMR) and showed that a single 1000 mg dose of lead to a significant number of glucocorticoid-free remissions after 1 year. 

Read Article
guidelines.jpg (keep)

British Society of Rheumatology Plans Revision of Systemic Sclerosis Guideline

Jack Cush, MD

British Society for Rheumatology (BSR) last published its guideline for systemic sclerosis (SSc) in 2016. Given the many advances in the field the BSR has outlined their plans to update the management of SSc.

Read Article
RheumNow Podcast square

Night Splinting for Carpal Tunnel (3.24.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com.  This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.

Read Article
ANCA, vasculitis, test

Updated AAV Treatment Recommendations

EurekAlert!

AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). This variety can make management challenging.

Read Article
obesity.knee_.arthritis.jpg

Metformin Reduces Osteoarthritis Risk

MedPage Today

Metformin may help cut the risk of osteoarthritis (OA) in those with type 2 diabetes, researchers reported.

Read Article
SI AS SpA ACR

Spondyloarthritis Innovations

Robert Chao, MD

The second day of RheumNow Live 2023 ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.

Read Article
Dutch Biologic Monitor surveys of RA, PsA, axSpA pts on etanercept or adalimumab, looked at adverse drug reactions. Among 748 consecutive pts on biologics, women had more ADRs (55%) than men (38%). nature ofreported ADRs differed betw sexes (p = 0.02). https://t.co/fGRgX4IJLR https://t.co/FJE7BrKPfQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Pooled data from 3 RCTs in PsA compared tofacitinib vs. adalimumab in 816 pts. Baseline, women had higher TJC, enthesitis, HAQ-DI, FACIT-F (Males more dactylitis). Sexes had equal ACR20/50/70, PASI75, ∆HAQ-DI, & persistence, but females less achieved MDA https://t.co/LICWVjI2kH https://t.co/8RipVIEWyJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Inflammasome inhibitors in development: - RRx-001 in cancer, ALS, parkinsons - OLT1177 in OA knee, gout, Schnitzlers - DFV890 in CAPs, knee OA - IZD174/334 in CAPS - ZYIL1 CAPS https://t.co/7E2jdx9TPA https://t.co/R5Uu5mjIym

Links:

Dr. John Cush RheumNow ( View Tweet)
The Origin Story: Women in Rheumatology--The XX Factor When asked to run a campaign to highlight the achievements and challenges of women in rheumatology, I was ecstatic because we have has so many heroines who have contributed to our field. https://t.co/ucQIPjQ8Tu https://t.co/g81EtAwYYL

Links:

Dr. John Cush RheumNow ( View Tweet)
Drs. Tate and Dao will be leading discussions on Women in Rheumatology, the XX Factor. Sign up to attend our Tuesday Night Rheumatology series. @uptoTate @KDAO2011 https://t.co/ciEAY1SJdg https://t.co/dlCfXItAxN

Links:

Dr. John Cush RheumNow ( View Tweet)
Tomorrow! Join us for Tuesday Night Rheumatology. Our panelists will discuss the challenges they have faced trying to manage a career and family life, as well as provide advice and strategies for managing competing priorities and obligations. https://t.co/OlP0pupkMV https://t.co/pZQMASafcG

Links:

Dr. John Cush RheumNow ( View Tweet)
Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Responses to be 48% and 52% (vs PBO 29% and 32%). >75% maintained response out to wk 48; at wk 48, a 75% HS response seen in 55%. https://t.co/ZxJylP7IUk https://t.co/Kmx1dkHycM

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center study of 320 Difficult to Rx RA (D2TRA) pts, found 76 EULAR-D2TRA pts (24%). D2TRA more likely to be lower socio-economic, RF+, have ILD, higher DAS28-CRP and were more likely to respond to rituximab and JAK inhibitors https://t.co/aEvP6WDvQu https://t.co/FQJvo81FbM

Links:

Dr. John Cush RheumNow ( View Tweet)
The Biosimilar "Buy In" Dr. Rachel Tate, @uptotate , shared insights into these key discussions during RheumNow Live. https://t.co/dD3uZCNQEo https://t.co/MuN91Oqbvo

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves Citrate-Free Formulation of Hyrimoz, a Biosimilar to Humira - but adalimumab-adaz HCF wont be available in USA until July 1, 2023 https://t.co/RRjxPW5I4O https://t.co/hf6NlkGG7W

Links:

Dr. John Cush RheumNow ( View Tweet)
Biosimilars are coming! Multiple adalimumab biosimilars this year - will we see a dramatic price difference? @RheumNow #RNL2023 https://t.co/8vdtXtEGOO
Robert B Chao, MD doctorRBC ( View Tweet)
Biosimilar to biosimilar switching of Infliximab , ⁦@RheumNow⁩ Kavanaugh #RNL2023 Communications is a key always. Discuss with your patient always, and show them the data. https://t.co/d7Nq6LoJYQ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Year in Review by Dr. Cush and Dr. Kavanaugh Combo biologic therapy? Phase II study from GI colleagues for UC Guselkumab + golimumab - no additional safety concerns - improved clinical response - extrapolate to rheumatology use? #RNL2023 @RheumNow https://t.co/DirAovm1AX
Robert B Chao, MD doctorRBC ( View Tweet)
How is a biosimilar approved? Comparative effectiveness study for the reason that the medication was initial approved required, not for other indications Jonathan Kay shows ex of ETN-ykro vs reference ETN in RA Non-inferior in immunogenicity, safety, efficacy @RheumNow #RNL2023 https://t.co/OOHie9Qr5t
Eric Dein ericdeinmd ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×